Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

Interestingly, early reports suggest that retatrutide may actually prove to be more effective at weight loss than many currently-available alternatives. In fact, if all goes as planned ...

"Not all GLP-1s are the same." Retatrutide, the 'King Kong' drug to mimic bariatric surgery Eli Lilly isn't pivoting away from weekly weight loss injections entirely. It's also working on another ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Nearly a year ago, Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results from a clinical trial with an experimental weight loss ...